



**FIRST
AND ONLY**
SGLT2i with
an indication
in HFrEF^{2*}



FORXIGA is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visit.¹

Please consult the Product Monograph at www.azinfo.ca/forxiga/pm367 for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-668-6000.

DOWNLOAD THE FORXIGA PRODUCT MONOGRAPH AT FORXIGA.CA

HFrEF: heart failure with reduced ejection fraction; SGLT2i: sodium-glucose co-transporter 2 inhibitor.

* Comparative clinical significance has not been established.

REFERENCES: 1. Product FORXIGA Monograph. AstraZeneca Canada Inc. June 29, 2020. 2. AstraZeneca data on file.

FORXIGA® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.



© 2020 AstraZeneca Canada Inc. CA-3187E

